JMKX000197

DRUG3 trials

Sponsors

Jemincare, Shanghai Jeyou Pharmaceutical Co., Ltd.

Conditions

Malignant Pleural EffusionMalignant Pleural Effusions (Mpe)

Phase 1

A Phase I Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion

JemincareMalignant Pleural Effusion

Start: 2023-05-22End: 2025-05-01Target: 78Updated: 2023-06-28

A Phase Ib Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion

RecruitingNCT06740019

JemincareMalignant Pleural Effusions (Mpe)

Start: 2024-12-28End: 2026-11-30Target: 30Updated: 2025-04-04

Phase 2

A Phase II Study to Evaluate JMKX000197 Injection Versus Cisplatin in the Treatment of Malignant Pleural Effusion

Not yet recruitingNCT07649369

Shanghai Jeyou Pharmaceutical Co., Ltd.Malignant Pleural Effusions (Mpe)

Start: 2026-08-17End: 2028-08-14Target: 120Updated: 2026-06-16

Related Papers

STING agonist JMKX000197 infusion in patients with malignant pleural effusion: Preliminary results from a prospective phase Ib study.

Journal of Clinical Oncology2026-05-27